SCHEMBL1780700

SCHEMBL1780700

CC(C)(C)OC(=O)N1CCC2(CC1)CCN(c1ccc(Br)cn1)CC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 6/20 0.51
HSD17B10 Q99714 3/20 0.50
CYP3A4 P08684 2/20 0.50
TSHR P16473 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2D6 P10635 1/20 0.50
DDB1 Q16531 1/20 0.48
CRBN Q96SW2 1/20 0.48
CYP11B2 P19099 1/20 0.47
GPR119 Q8TDV5 6/20 0.47
AKR1C3 P42330 1/20 0.46
CKS1B P61024 1/20 0.46
SKP1 P63208 1/20 0.46
SKP2 Q13309 1/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29455974 1.00 RET (0.51) RETHSD17B10CYP3A4TSHRCYP2C19
SCHEMBL29455847 0.93 CYP11B2 (0.56) RETDDB1CRBNCYP11B2GPR119
SCHEMBL22137606 0.93 RET (0.52) RETHSD17B10CYP3A4TSHRCYP2C19
SCHEMBL1753703 0.92 RET (0.51) RETHSD17B10CYP3A4TSHRCYP2D6
SCHEMBL30392218 0.92 RET (0.51) RETDDB1CRBNCYP11B2GPR119
SCHEMBL26100649 0.92 RET (0.51) RETDDB1CRBNCYP11B2GPR119
SCHEMBL30480343 0.89 AKR1C3 (0.57) RETDDB1CRBNGPR119AKR1C3
SCHEMBL594352 0.89 AKR1C3 (0.57) RETDDB1CRBNGPR119AKR1C3
SCHEMBL29712339 0.88 AKR1C3 (0.56) RETDDB1CRBNGPR119AKR1C3
SCHEMBL30010609 0.86 RET (0.51) RETHSD17B10CYP3A4TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943630-B2 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-05-17 US disclosed
EP-1917264-B1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-11-17 EP disclosed
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors ANIONA APS (DK) 2009-04-30 US disclosed
EP-1917264-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-05-07 EP disclosed
WO-2007000463-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC6A3 RET 1072/4885HSD17B10 617/4885CYP3A4 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.